TG Therapeutics (NASDAQ:TGTX) Trading Up 9.5% – Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX) shares traded up 9.5% on Friday . The company traded as high as $39.94 and last traded at $40.57. 1,348,486 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 2,977,866 shares. The stock had previously closed at $37.06.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TGTX. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Up 10.1 %

The stock has a fifty day simple moving average of $31.52 and a 200 day simple moving average of $28.83. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $6.41 billion, a P/E ratio of -408.61 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors have recently made changes to their positions in the business. State Street Corp increased its holdings in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Clearbridge Investments LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter worth $55,237,000. Principal Financial Group Inc. raised its holdings in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares during the period. Raymond James Financial Inc. bought a new position in TG Therapeutics in the 4th quarter worth $14,508,000. Finally, Braun Stacey Associates Inc. purchased a new position in TG Therapeutics during the fourth quarter valued at $13,328,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.